Ex-Vivo Gene Therapy Approach for Continuous Delivery of BDNF and Its Potential Use for Neurological Disorders (P02.013)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P02.013-P02.013
Author(s):  
A. Gomez-Vargas ◽  
G. Hortelano ◽  
M. Rathbone
2006 ◽  
Vol 13 ◽  
pp. S420
Author(s):  
Enrico Pola ◽  
Wanda Lattanzi ◽  
Giandomenico Logroscino ◽  
Giovanni Pecorini ◽  
Anna Tampieri ◽  
...  

2013 ◽  
Vol 4 (1) ◽  
Author(s):  
Antonio Filareto ◽  
Sarah Parker ◽  
Radbod Darabi ◽  
Luciene Borges ◽  
Michelina Iacovino ◽  
...  

2005 ◽  
Vol 16 (1-3) ◽  
pp. 37-43 ◽  
Author(s):  
Chun-Li Duan ◽  
Yue Su ◽  
Chun-Li Zhao ◽  
Ling-Ling Lu ◽  
Qun-Yuan Xu ◽  
...  

2017 ◽  
Vol 121 (suppl_1) ◽  
Author(s):  
Benjamin Strauss ◽  
Yassine Sassi ◽  
Irene C Turnbull ◽  
Carlos Bueno-Beti ◽  
Erik Kohlbrenner ◽  
...  

Background: Pulmonary Arterial Hypertension (PAH) is a major cause of mortality due, in large part to right ventricular (RV) failure. Its electrophysiological (EP) effects however are poorly defined. Recently, a gene therapy approach targeting SERCA2a (S2A) to the lungs improved RV mechanical function in a rodent PAH model. Whether this approach improves myocardial EP properties remains unknown. Methods: Male Sprague Dawley rats received a subcutaneous injection of monocrotaline (MCT 60mg/kg) leading to PAH induced RV failure. Three wks later, rats underwent intratracheal delivery of aerosolized AAV1.S2A (1E11 gc, N=6) or no treatment (MCT, N=7). Age matched rats served as controls (CTRL, N=5). The EP substrate and risk of VT were assessed using high resolution optical action potential (AP) mapping in ex vivo perfused hearts. Results: MCT (6/7) but not CTRL (0/5) hearts were prone to pacing-induced VT (P<0.01). S2A gene therapy markedly suppressed the incidence of VT to <15% (P<.05 vs MCT). Investigation of the EP substrate revealed complete reversal of slow myocardial conduction in S2A treated compared to untreated MCT rats (Fig A, B) . AP duration (APD) and heterogeneity were increased in MCT and partially reversed by AAV1.S2A. Underlying the rise in heterogeneity was selective APD prolongation on the RV side causing >90 degree clockwise shift in the orientation of the transepicardial gradient, an effect which was not reversed by AAV1.S2A (Fig C arrows) . Conclusion: S2A gene therapy to the lungs ameliorates PAH induced EP remodeling and arrhythmia propensity. Our findings highlight for the first time the utility of a non-cardiac gene therapy approach for arrhythmia suppression.


Immunobiology ◽  
2020 ◽  
Vol 225 (1) ◽  
pp. 151862
Author(s):  
David Wilson Ferreira ◽  
Cristina Ulecia-Morón ◽  
Perla Abigail Alvarado-Vázquez ◽  
Katharine Cunnane ◽  
Carolina Moracho-Vilriales ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document